BEAM · Beam Therapeutics Inc. · Metrics
$20.90
-0.04 (-0.19%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Market Cap
$2.16B
Shares
103.50M
Volume · Nov 20
3.89M
Avg daily vol (3M)
2.05M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
BEAM metrics
86 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$20.90
Market cap
$2.16B
Price action
23 metricsPrice change (1W)
-8.5%
Price change (30D)
-14.9%
Price change (3M)
-29.8%
Price change (6M)
-27.0%
Price change (YTD)
-24.6%
Price change (1Y)
+1.5%
Trailing year
Price change (5Y)
-76.7%
52-week high
$37.92
52-week low
$20.60
Change from 52-week high
-44.9%
Change from 52-week low
+1.5%
Annualized volatility
73.0%
Annualized volatility (3M)
67.8%
Implied volatility (30D)
94.6%
IV rank (1Y)
55.6
IV percentile (1Y)
86.1
Beta
2.3
RSI (14D)
35.9
Price vs SMA 50
-15.2%
Price vs SMA 200
-24.6%
Avg volume (3M)
2.05M
Relative volume
1.9
Average dollar volume
$51.57M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
103.50M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
8.3×
reciprocal yield 12.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
14.8×
reciprocal yield 6.8%
P / book
2.3
reciprocal yield 44.0%
FCF yield
-18.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-5.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
10.1×
reciprocal yield 9.9%
EV / revenue historical average (5Y)
11.2×
reciprocal yield 8.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-10-27
Profitability
9 metricsGross margin
—
Operating margin
-267.7%
Trailing 12 months
Net margin
-73.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$392.54M
Net income (TTM)
−$108.35M
Trailing 12 months
Diluted EPS (TTM)
$-0.85
FCF margin
-271.6%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-96.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$146.64M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.1%
Year over year · more shares
Revenue CAGR (3Y)
+31.9%
Revenue CAGR (5Y)
+466.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-11.4%
Return on assets
-8.5%
Debt / equity
0.1
Current ratio
13.0
EBITDA (TTM)
−$370.41M
Free cash flow (TTM)
−$398.24M
Quick ratio
13.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$943.51M
Latest balance sheet
Cash & equivalents
$213.27M
Total assets
$1.27B
Total debt
$100.36M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$388.65M
Capital expenditures (TTM)
$9.59M
R&D (TTM)
$409.00M
SG&A (TTM)
—
Stock compensation (TTM)
$77.33M
R&D / revenue
278.9%
Stock compensation / revenue
52.7%
Ownership (13F)
9 metrics13F filers
264
13F filer change QoQ
-14
Institutional ownership
108.5%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.2%
Holder tenure
18.0
Price vs estimated holder cost
-27.0%
Ownership (registered funds)
1 metricsIndex-fund ownership
21.0%
Short interest
3 metricsShort interest
25.2%
Latest settlement · 13.7 days to cover
Days to cover
13.7d
Short-squeeze score
69 / 100
Insider activity
2 metricsNet insider buying (90D)
−$1.19M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1745999
CUSIP
07373V105
13F (30d)
270 filings
247 filers
Visit website
Investor relations